News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
619,409 Results
Type
Article (36757)
Company Profile (115)
Press Release (582537)
Multimedia
Podcasts (41)
Webinars (7)
Section
Business (172272)
Career Advice (2749)
Deals (32304)
Drug Delivery (87)
Drug Development (72405)
Employer Resources (158)
FDA (15550)
Job Trends (14516)
News (299465)
Policy (28858)
Tag
2024 BioForest Standard (1)
2024 BioMidwest Digital (1)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (15)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (8)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (5)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (2)
Academia (2664)
Academic (1)
Accelerated approval (4)
Adcomms (23)
Allergies (87)
Alliances (43153)
ALS (94)
Alzheimer's disease (1411)
Antibody-drug conjugate (ADC) (105)
Approvals (15561)
Artificial intelligence (246)
Autoimmune disease (26)
Automation (15)
Bankruptcy (288)
Best Places to Work (12092)
BIOSECURE Act (17)
Biosimilars (96)
Biotechnology (83)
Bladder cancer (65)
Brain cancer (25)
Breast cancer (270)
Cancer (2108)
Cardiovascular disease (164)
Career advice (2279)
Career pathing (31)
CAR-T (146)
Cell therapy (417)
Cervical cancer (18)
Clinical research (59115)
Collaboration (817)
Compensation (522)
Complete response letters (19)
COVID-19 (2459)
CRISPR (39)
C-suite (242)
Cystic fibrosis (103)
Data (2117)
Decentralized trials (1)
Denatured (8)
Depression (39)
Diabetes (254)
Diagnostics (6591)
Digital health (17)
Diversity (3)
Diversity, equity & inclusion (38)
Drug discovery (115)
Drug pricing (85)
Drug shortages (19)
Duchenne muscular dystrophy (89)
Earnings (68036)
Editorial (38)
Employer branding (21)
Employer resources (138)
Events (102037)
Executive appointments (736)
FDA (16769)
Featured Employer (61)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (739)
Gene editing (103)
Generative AI (20)
Gene therapy (295)
GLP-1 (601)
Government (4034)
Grass and pollen (5)
Guidances (47)
Healthcare (19825)
Huntington's disease (21)
IgA nephropathy (23)
Immunology and inflammation (104)
Indications (29)
Infectious disease (2597)
Inflammatory bowel disease (138)
Inflation Reduction Act (9)
Influenza (50)
Intellectual property (97)
Interviews (542)
IPO (16156)
IRA (32)
Job creations (2862)
Job search strategy (1891)
Kidney cancer (11)
Labor market (26)
Layoffs (418)
Leadership (21)
Legal (6360)
Liver cancer (63)
Lung cancer (293)
Lymphoma (136)
Machine learning (5)
Management (59)
Manufacturing (283)
MASH (65)
Medical device (13975)
Medtech (13980)
Mergers & acquisitions (16767)
Metabolic disorders (597)
Multiple sclerosis (74)
NASH (13)
Neurodegenerative disease (92)
Neuropsychiatric disorders (24)
Neuroscience (1933)
NextGen: Class of 2025 (6709)
Non-profit (4823)
Northern California (2625)
Now hiring (28)
Obesity (292)
Opinion (225)
Ovarian cancer (74)
Pain (89)
Pancreatic cancer (78)
Parkinson's disease (154)
Partnered (20)
Patents (226)
Patient recruitment (106)
Peanut (49)
People (51567)
Pharmaceutical (33)
Pharmacy benefit managers (18)
Phase I (18418)
Phase II (26242)
Phase III (19578)
Pipeline (1120)
Policy (117)
Postmarket research (2017)
Preclinical (7507)
Press Release (62)
Prostate cancer (94)
Psychedelics (30)
Radiopharmaceuticals (255)
Rare diseases (380)
Real estate (4889)
Recruiting (63)
Regulatory (20436)
Reports (26)
Research institute (2438)
Resumes & cover letters (449)
Rett syndrome (4)
RNA editing (3)
RSV (43)
Schizophrenia (68)
Series A (120)
Series B (83)
Service/supplier (6)
Sickle cell disease (57)
Southern California (2270)
Special edition (12)
Spinal muscular atrophy (146)
Sponsored (25)
Startups (3029)
State (2)
Stomach cancer (7)
Supply chain (65)
Tariffs (27)
The Weekly (32)
United States (22871)
Vaccines (619)
Venture capitalists (33)
Weight loss (170)
Women's health (25)
Worklife (17)
Date
Today (213)
Last 7 days (572)
Last 30 days (2594)
Last 365 days (33515)
2025 (10046)
2024 (35955)
2023 (41286)
2022 (52113)
2021 (57039)
2020 (55564)
2019 (48731)
2018 (36629)
2017 (32101)
2016 (30368)
2015 (35472)
2014 (24629)
2013 (19205)
2012 (20726)
2011 (21532)
2010 (18623)
Location
Africa (758)
Alabama (57)
Alaska (7)
Arizona (156)
Arkansas (12)
Asia (36107)
Australia (6439)
California (5964)
Canada (1976)
China (499)
Colorado (265)
Connecticut (278)
Delaware (141)
Europe (83573)
Florida (892)
Georgia (214)
Idaho (58)
Illinois (532)
India (23)
Indiana (311)
Iowa (9)
Japan (153)
Kansas (100)
Kentucky (26)
Louisiana (10)
Maine (70)
Maryland (867)
Massachusetts (4579)
Michigan (237)
Minnesota (388)
Mississippi (2)
Missouri (88)
Montana (31)
Nebraska (25)
Nevada (61)
New Hampshire (67)
New Jersey (1707)
New Mexico (30)
New York (1705)
North Carolina (1011)
North Dakota (8)
Northern California (2625)
Ohio (206)
Oklahoma (14)
Oregon (35)
Pennsylvania (1345)
Puerto Rico (11)
Rhode Island (33)
South America (1081)
South Carolina (21)
South Dakota (1)
Southern California (2270)
Tennessee (103)
Texas (887)
Utah (185)
Virginia (146)
Washington D.C. (59)
Washington State (557)
West Virginia (3)
Wisconsin (56)
619,409 Results for "bioarctic ab".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
The Nomination Committee’s proposal for the election of Board members and Chairperson of the Board in BioArctic AB
BioArctic AB hereby announces that the Nomination Committee for BioArctic AB presents the following proposals regarding the resolution on the number of board members and the election of board members and Chairperson of the Board at the Annual General Meeting on May 22, 2024.
April 16, 2024
·
4 min read
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
BioArctic AB announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic’s proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidate.
April 20, 2024
·
4 min read
Drug Development
BioArctic: Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer’s European Grand Prix for his contributions to science and treatment of Alzheimer’s disease
BioArctic AB announced that BioArctic’s founder, Professor Lars Lannfelt, was awarded the European Grand Prix for his research on Alzheimer’s disease at the anniversary gala for La Fondation Recherche Alzheimer in Paris on March 18.
March 19, 2024
·
5 min read
BioArctic’s partner Eisai presents updated sales simulation for Leqembi® at its annual press conference
BioArctic AB’s partner Eisai published a presentation including a simulation of potential future sales for Leqembi, the world’s first fully approved disease-modifying treatment for Alzheimer’s disease.
March 7, 2024
·
3 min read
BioArctic’s focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm
BioArctic AB’s commitment to its Sustainable Innovation approach - combining scientific progress with responsible business practices and a dedication to environmental, social, and corporate governance principles - has earned the company a place on the new Nasdaq OMX Sweden Small Cap 30 ESG Responsibility Index launched.
April 10, 2024
·
3 min read
BioArctic: Latest data on lecanemab to be presented at the 2024 AD/PD™ congress
BioArctic AB announced that the company and its partner Eisai will present new data on lecanemab at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, to be held in Lisbon, Portugal and virtually, March 5-9.
February 29, 2024
·
9 min read
Press Releases
AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia
April 23, 2025
·
7 min read
The European Medicines Agency’s Scientific Advisory Group (SAG) to discuss the Marketing Authorisation Application for lecanemab: BioArctic
BioArctic AB’s partner Eisai announced that the Scientific Advisory Group will convene to discuss the Marketing Authorisation Application of lecanemab, which is currently under review by the European Medicines Agency.
January 11, 2024
·
6 min read
BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress
BioArctic’s founder, Professor Lars Lannfelt, presented data on the binding properties of the anti-amyloid-beta antibody lecanemab and other anti Aβ antibodies.
March 11, 2024
·
7 min read
BioArctic receives patent in Japan for new antibodies targeting Parkinson’s disease
BioArctic AB announced that the Japanese Patent Office is granting a new drug substance patent for the antibody BAN0805, invented by BioArctic as a potential treatment of Parkinson’s disease.
August 23, 2023
·
2 min read
1 of 61,941
Next
